Report

Atossa Genetics - Endoxifen to start Phase II studies shortly

Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor (ER) antagonist, is being advanced in topical form to treat high mammographic breast density (MBD), and also as an oral drug to prevent cancer recurrence in women refractory to tamoxifen. The company plans to raise $20m in equity through a rights offering in May 2018, which we believe should fund the Phase II endoxifen trials through completion.
Underlying
Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company's primary program is the development of Endoxifen, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is developing an oral and topical form of Endoxifen. The company's Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density; breast cancer in the window of opportunity between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Pooya Hemami

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch